Amedisys (AMED) PT Cut to $47 at Mizuho Following Results

Mizuho Securities analyst Sheryl Skolnick reiterated a Neutral rating and lowered her price target on Amedisys (NASDAQ: AMED) to $47.00 following results.

Skolnick commented, "What the new team has done for AMED in a very short period of time seems close to a miracle given the company's starting point: Training 11k people & 50% of agencies on a new IT system at one time, dealing with a 1,000-year flood and only missing by $0.05? But, we want to see 4Q16 execution against our more de-risked (lower) estimates. Still, the stock seems modestly undervalued, but not by enough to rate a 'Buy.' New $47 PT still values 38% growth rather richly. Let's let them get there."

For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.

Shares of Amedisys closed at $43.78 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• AvidBank Holdings Inc. (AVBH) PT Lowered to $23 at Piper Sandler
• Yageo Corp. (2327:TT) (YAGOY) PT Lowered to NT$656 at HSBC